Shots:
- Abogen has entered into a licensing & option agreement, granting Novartis an exclusive worldwide license to ABO2203, as well as options to exclusively license other potential programs that leverage Abogen’s RNA platform
- As per the deal, Abogen will receive ~$575M upfront &, if all options on all programs are exercised, Abogen will gain ~$7.2B in development, regulatory and commercial milestone payments, plus royalties on future product sales
- ABO2203 is a novel mRNA-encoded CD19×CD3 T-cell engager designed to reset B cells by utilizing mRNA to direct endogenous production of T-cell engagers in vivo, with potential to transform treatment landscapefor autoimmune diseases
Ref: Businesswire | Image: Abogen & Novartis | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
